Authors: Leebeek, FWG Stadhouders, NAM van Stein, D Gomez-Garcia, EB Kappers-Klunne, MC

Citation: Fwg. Leebeek et al., Hypercoagulability states in upper-extremity deep venous thrombosis, AM J HEMAT, 67(1), 2001, pp. 15-19

Authors: Muller, AF Leebeek, FWG Janssen, JAMJL Lamberts, SWJ Hofland, L Van Der Lely, AJ

Citation: Af. Muller et al., Acute effect of pegvisomant on cardiovascular risk markers in healthy men:Implications for the pathogenesis of atherosclerosis in GH deficiency, J CLIN END, 86(11), 2001, pp. 5165-5171

Authors: Lisman, T Leebeek, FWG Mosnier, LO Bouma, BN Meijers, JCM Janssen, HLA Nieuwenhuis, HK De Groot, PG

Citation: T. Lisman et al., Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is notassociated with increased plasma fibrinolysis, GASTROENTY, 121(1), 2001, pp. 131-139

Authors: Brouwers, GJ Vos, HL Leebeek, FWG Bulk, S Schneider, M Boffa, M Koschinsky, M van Tilburg, NH Nesheim, ME Bertina, RM Garcia, EBG

Citation: Gj. Brouwers et al., A novel, possibly functional, single nucleotide polymorphism in the codingregion of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels, BLOOD, 98(6), 2001, pp. 1992-1993

Authors: van Krimpen, J Leebeek, FWG Dippel, DWJ Garcia, EG

Citation: J. Van Krimpen et al., Prothrombin gene variant (G20210A) in a patient with cerebral venous sinusthrombosis, CLIN NEUROL, 101(1), 1999, pp. 53-55

Authors: Leebeek, FWG Schipperus, MR van Vliet, HHDM

Citation: Fwg. Leebeek et al., Coagulation factor levels in solvent/detergent-treated plasma, TRANSFUSION, 39(10), 1999, pp. 1150-1151